Skip to main
APGE
APGE logo

APGE Stock Forecast & Price Target

APGE Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Apogee Therapeutics Inc. is positioned strongly in the biotechnology sector due to its approach of developing monoclonal antibodies (mAbs) targeting established mechanisms for diseases with high unmet need, such as atopic dermatitis and chronic obstructive pulmonary disease. The company anticipates a significant market expansion within the atopic dermatitis sector, projected to grow to approximately $30 billion by 2035, supported by reduced competition and increased validation of its products. Furthermore, success in the upcoming Phase 2 clinical trial of the candidate APG777 is expected to not only enhance the company's product portfolio but also potentially lead to the development of a best-in-class monotherapy, creating substantial financial upside.

Bears say

Apogee Therapeutics faces substantial risks to its stock performance, primarily due to potential market entry of biosimilars like REGN/SAN-PAR's Dupixent before 2035-37, which may erode its competitive positioning. The biotechnology company's clinical programs, specifically APG777, carry uncertainties surrounding their safety, efficacy, and tolerability compared to existing treatments, which could lead to disappointing trial results and unforeseen development delays. Furthermore, the atopic dermatitis market remains largely under-penetrated, with only about 10% of eligible patients currently receiving systemic treatments, indicating a challenging market landscape that may hinder Apogee's growth potential.

APGE has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apogee Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apogee Therapeutics Inc (APGE) Forecast

Analysts have given APGE a Strong Buy based on their latest research and market trends.

According to 1 analysts, APGE has a Strong Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $116, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $116, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apogee Therapeutics Inc (APGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.